Perspectives

Episode #15: Nurturing growth: Measuring the return from pharmaceutical innovation 2021

Life Sciences Connect

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines.

Let’s make this work.

Change your targeting/advertising cookie settings to access this feature.

On this episode of Life Science’s Connect podcast, we discuss these issues further with our panel of experts:

  • Colin Terry, UK Life Sciences and Healthcare Consulting Leader
  • Neil Lesser, US Life Sciences R&D Leader

And of course, our host, Karen Taylor, Research Director, Centre for Health Solutions, Deloitte

In episode fifteen of the Life Science Connect podcast, we dive into the conversation around our annual R&D Measuring the return from pharmaceutical innovation series report. This report analyses the projected return on investment that biopharma companies can expect to earn from their late-stage pipelines.

This year, we have witnessed a large improvement in IRR with some companies seeing impressive improvements in peak sales projections. Moreover, the average cost to develop an asset has declined as the industry begins to capitalise on improvements in efficiency.

Speakers

Karen Taylor
Research Director, UK Centre for Health Solutions
Deloitte

Karen is the Research Director of the Centre for Health Solutions. She supports the Healthcare and Life Sciences practice by driving independent and objective business research and analysis into key industry challenges and associated solutions; generating evidence based insights and points of view on issues from pharmaceuticals and technology innovation to healthcare management and reform.

Read more

Colin Terry
Partner, UK Life Sciences & Healthcare industry
Deloitte

Colin is a Partner in our Life Sciences practice. He has been with Deloitte since 2011 working in the US firm, until 2014 when he moved to the UK practice. Colin’s client advisory work in the Life Sciences sector ranges across strategy and operations focused on the R&D function including operating model development and implementation as well as post-merger integration (PMI).

Read more

Neil Lesser
Principl, Consulting
Deloitte

Neil is a principal with Deloitte Consulting LLP in the Life Sciences strategy practice and a leader in the Research & Development strategy practice. He joined Deloitte in 1998 and works with life sciences executives creating and implementing strategies that drive productivity, efficiency, and value.

Read more

Find out more

If you are interested in any of the topics discussed during this episode and want more information, please explore some useful links below:

  • Stay up to date on industry issues by subscribing to our blog.

Life Sciences Connect

To see the full collections of episodes so far, please visit the Life Sciences Connect podcast library.

 
Did you find this useful?
Life Sciences Connect

Our podcast series on the Life Sciences and Healthcare Industries

The Life Sciences Catalyst